BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ciforadenant readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ciforadenant\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05501054-1626@assetmemo.bio
DTSTAMP:20261121T005725Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Ciforadenant: Phase 1/2 readout est. (NCT05501054)
DESCRIPTION:Ciforadenant\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 
 1b/2 Trial of Ipilimumab\, Nivolumab\, and Ciforadenant (Adenosine A2a Rec
 eptor Antagonist) in First-line Advanced Renal Cell Carcinoma.\nEstimated 
 primary completion: 1 November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ciforadenant#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05501054
URL:https://assetmemo.bio/drug/ciforadenant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
